A trio of novel cancer agent applications announced last week illustrates the breadth of oncology R&D, from targeted kinase inhibitors (Taiho Pharmaceutical Co. Ltd.’s futibatinib) to antibody-drug conjugates (ImmunoGen, Inc.’s mirvetuximab soravtansine) and radioimmunotherapy (Y-mAbs Therapeutics Inc.’s 131I-omburtamab).
Other recently submitted products aim to shake up established spaces. Outlook Therapeutics, Inc. plans to take on the widespread use of compounded and repackaged IV bevacizumab for ophthalmic use with Lytenava, its intravitreal formulation of the angiogenesis inhibitor. CorMedix Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?